Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Liabilities for 3 consecutive years, with $564.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 62.83% to $564.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $564.2 million, a 62.83% increase, with the full-year FY2025 number at $564.2 million, up 62.83% from a year prior.
  • Total Liabilities was $564.2 million for Q4 2025 at Kura Oncology, up from $406.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $564.2 million in Q4 2025 to a low of $30.8 million in Q1 2023.
  • A 3-year average of $199.0 million and a median of $53.4 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: grew 25.62% in 2024, then soared 676.99% in 2025.
  • Kura Oncology's Total Liabilities stood at $51.7 million in 2023, then soared by 570.74% to $346.5 million in 2024, then skyrocketed by 62.83% to $564.2 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Total Liabilities are $564.2 million (Q4 2025), $406.8 million (Q3 2025), and $376.9 million (Q2 2025).